Equity Field Notes from temporal sources

[DanWebzster]

OVID has two Ph2 studies to read out in 2018

Data for its treatment for Angelman's syndrome is expected Q-3/2018.

Data for rare epileptic encephalopathies (aka Dravets Syndrome) will be read out H-2/2018.

The compound for Angelmans (OV-101) is licensed from Lundbeck who took it all the way thru Ph3 for insomnia, then decided it was not commercially viable.

The compound for Dravets is licensed from Takeda ex-Asia.

Both treatments could face stiff competition if approved. Also, there is a pre-clinical gene therapy (GT) for Angelman's that could render OV-101 obsolete.

Cash runway is deep into 2019.

This a stock to stalk short on promising data read-outs.